Menveo
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Menveo | — | 2010-03-15 | europa.eu ↗ |
| Refused (EMA) | EU (EMA) | Menveo | — | 2009-12-17 | europa.eu ↗ |
Trials 61 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06128733 | Oct 2023 → Aug 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT04324606 | Apr 2020 → Feb 2025 | Coronaviridae infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT04056117 | Sep 2019 → Sep 2022 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01782066 | Jan 2013 → Feb 2014 | meningococcal infection | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT07286370 | Apr 2026 → Apr 2028 expected | salmonellosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT06523231 | Apr → Aug 2025 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 2 | NCT05082285 | Nov 2021 → Mar 2025 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04645966 | Nov 2020 → Sep 2022 | meningococcal infection | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT02548078 | Nov 2015 → May 2017 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02324751 | Sep 2015 → Dec 2017 | typhoid fever | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT02097849 | Feb 2015 → May 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01018732 | Jan → Jul 2010 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00715910 | Jul 2008 → Apr 2013 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00488683 | Jul 2007 → May 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00560313 | Jul 2007 → Nov 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00427908 | Feb → Dec 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00356369 | Dec 2006 → Sep 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00310856 | Jun 2005 → Nov 2006 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00262041 | Oct 2004 → Mar 2006 | meningococcemia | Novartis Vaccines | Completed | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT07133178 | Feb → Dec 2026 | chikungunya | Valneva Austria GmbH | Withdrawn | No outcome recorded |
| Phase 3 | NCT04819113 | Apr 2021 → Sep 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04440163 | Jun 2020 → Jul 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03189745 | Aug 2017 → Apr 2018 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03135834 | Apr 2017 → Oct 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02955797 | Feb → Oct 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02986854 | Dec 2016 → Jul 2017 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02106390 | Jun 2014 → Oct 2016 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01839175 | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01725217 | Nov 2012 → Mar 2013 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01547715 | Mar 2012 → Apr 2014 | bacterial meningitis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01410474 | Aug 2011 → Jan 2012 | bacterial meningitis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01345721 | May → Sep 2011 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01266993 | Jan 2011 → Mar 2014 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01274897 | Dec 2010 → Mar 2011 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01214837 | Oct 2010 → Apr 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01214850 | Sep 2010 → Jan 2012 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01144663 | Jul 2010 → Jun 2012 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01148017 | Jul 2010 → Apr 2013 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01000311 | Nov 2009 → Nov 2011 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00856297 | Feb 2009 → Nov 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00616421 | Mar 2008 → Apr 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00614614 | Feb 2008 → Jul 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00626327 | Feb 2008 → Jul 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00514904 | Sep 2007 → Sep 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00518180 | Jul 2007 → Apr 2008 | human papilloma virus infection, meningococcal meningitis, pertussis, tetanus | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00465816 | Apr 2007 → Apr 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00450437 | Mar → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00474526 | Mar 2007 → Sep 2008 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00329849 | May 2006 → Mar 2007 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00329901 | Apr 2006 → May 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06436274 | Oct 2024 → Dec 2026 expected | HIV infectious disease, human papilloma virus infection | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04875819 | Apr 2021 → Dec 2026 expected | HIV infectious disease, meningococcal infection, pneumococcal infection | Thomas Benfield | Recruiting | No outcome recorded |
| Phase 4 | NCT03682939 | Feb 2019 → Jun 2020 | HIV infectious disease, meningococcal meningitis | St George's, University of London | Unknown | No outcome recorded |
| Phase 4 | NCT03694405 | Sep 2018 → Aug 2021 | meningococcal infection | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT02446691 | Jul 2015 → Dec 2017 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02072525 | Apr 2014 → Jun 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01823536 | May → Oct 2013 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT01766206 | Mar 2013 → Jan 2018 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01424644 | Sep 2011 → Dec 2012 | meningococcal meningitis | Novartis | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06116669 | Nov 2023 → Dec 2024 | iron deficiency anemia | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| — | NCT05919472 | Jul 2023 → Jul 2024 | iron deficiency anemia | Nicole Stoffel | Completed | No outcome recorded |
Also used as a comparator or background therapy in 40 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05739292 Comparator | Feb → May 2023 | meningococcal infection | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05743881 Comparator | Feb 2023 → Aug 2029 expected | respiratory syncytial virus infectious disease | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05073003 Comparator | Oct 2021 → Jun 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT04886154 Comparator | Jun 2021 → Feb 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03606512 Comparator | Jan 2019 → Nov 2021 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07320716 Comparator | Jan 2026 → Oct 2028 expected | diarrheal disease | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07183371 Comparator | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06213506 Comparator | Jan 2024 → Sep 2026 expected | salmonellosis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06106581 Comparator | Dec 2023 → Jul 2024 | chikungunya | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03929757 Background | Aug 2019 → Aug 2022 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03652610 Comparator | Sep 2018 → Jan 2019 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03433482 Comparator | Aug 2018 → Jul 2019 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03587207 Comparator | Jul → Dec 2018 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02676895 Comparator | Aug 2016 → Mar 2017 | shigellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02199691 Comparator | Jul 2014 → Oct 2015 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT02140762 Comparator | May → Nov 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01994629 Comparator | Nov 2013 → Apr 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01272180 Comparator | Aug → Oct 2011 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07204457 Comparator | Oct 2025 → Sep 2026 expected | meningococcal infection | EyeGene Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04400838 Comparator | May 2020 → Feb 2025 | COVID-19 | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT01192997 Comparator | Jun 2012 → Oct 2013 | meningococcal meningitis | Public Health England | Completed | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT06284915 Comparator | Mar 2024 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT05093829 Comparator | Mar 2022 → Mar 2023 | meningococcal meningitis | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT04707391 Comparator | Jan 2021 → May 2023 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04536051 Comparator | Jun 2020 → Sep 2021 | COVID-19 | University of Oxford | Unknown | No outcome recorded |
| Phase 3 | NCT03890367 Comparator | Sep 2019 → Oct 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03547271 Comparator | Dec 2018 → May 2023 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03691610 Comparator | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03673462 Comparator | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03537508 Comparator | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03165617 Comparator | May 2017 → Sep 2019 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 3 | NCT03077438 Comparator | Feb → Oct 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02509494 Comparator | Sep 2015 → Jun 2019 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01682876 Comparator | Oct 2012 → Jul 2013 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01453348 Comparator | Oct 2011 → Jan 2012 | hepatitis A virus infection, hepatitis B virus infection, meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00901940 Comparator | Jun 2009 → Oct 2010 | bacterial infectious disease with sepsis, meningitis | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00474487 Comparator | May → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03675256 Comparator | Dec 2018 → Feb 2024 | human papilloma virus infection | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT01593514 Comparator | Dec 2012 → Apr 2013 | bacterial infectious disease with sepsis, meningitis, meningococcal infection | University of Oxford | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-11-23 | Sanofi | European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older sanofi.com ↗ |
| 2020-04-24 | Sanofi | FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination sanofi.com ↗ |
| 2016-12-19 | Pfizer | Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older pfizer.com ↗ |
| 2015-10-01 | Pfizer | Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline pfizer.com ↗ |
| 2015-06-22 | Pfizer | Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline pfizer.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 106 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menveo | “This was the first study of laboratory workers who received both a conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Men ACWY-CRM, Menveo) and an...” PMID 21177912 ↗ Dec 201027“One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B...” NCT04875819 ↗ “MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy) is a quadrivalent meningococcal conjugate vaccine developed to help prevent invasive meningococcal disease caused by...” PMID 25075804 ↗ Jul 2014 “The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the...” NCT01593514 ↗ “Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.” PMID 21339701 ↗ Nov 2010 “The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo).” NCT00901940 ↗ “Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.” NCT02199691 ↗ “meningococcal serogroup A, C, W-135, and Y (Menveo®, GlaxoSmithKline Biologicals, S.A.)” NCT03165617 ↗ “GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo” NCT04886154 ↗ “Meningitec, NeisVacC, Menitorix, Menveo, Nimenrix” NCT02526394 ↗ “MenACWY (Menveo) vaccine” NCT03587207 ↗ “MenACWY-CRM (Menveo)” NCT01766206 ↗ “Menveo®” NCT06128733 ↗ “Menveo” NCT04400838 ↗ |
| Known as | 134612 | “GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)” NCT00427908 ↗1“Nimenrix (Meningococcal vaccine 134612)” NCT00465816 ↗ |
| Known as | ACWY Vax | “The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax).” NCT00901940 ↗ |
| Known as | Control (Men ACWY) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02324751 ↗ |
| Known as | GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo | “GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo” NCT04886154 ↗ |
| Known as | GSK134612 | “GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)” NCT00614614 ↗1“Nimenrix (GSK134612 vaccine)” NCT01266993 ↗ |
| Known as | MCV4-TT | “The immunogenicity and safety of MenACYW-TT (MenQuadfi®) were compared to another quadrivalent meningococcal conjugate vaccine, MCV4-TT (Nimenrix®), when administered in...” PMID 40665158 ↗ Jul 2025 |
| Known as | MenACWY | “The comparator was (meningococcal [Groups A, C, W-135, and Y] oligosaccharide diphtheria CRM197 conjugate vaccine [Men ACWY]).” NCT03165617 ↗ |
| Known as | MenACWY plain polysaccharide | “The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax).” NCT00901940 ↗ |
| Known as | MenACWY vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06116669 ↗ |
| Known as | MenACWY-CRM | “This was the first study of laboratory workers who received both a conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Men ACWY-CRM, Menveo) and an...” PMID 21177912 ↗ Dec 201036“Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55...” NCT02986854 ↗ “MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy) is a quadrivalent meningococcal conjugate vaccine developed to help prevent invasive meningococcal disease caused by...” PMID 25075804 ↗ Jul 2014 “This study compares the safety and immunogenicity of the Novartis Vaccines investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, with the licensed...” PMID 19476428 ↗ Jul 2009 “The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or...” PMID 21339701 ↗ Nov 2010 “This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate...” PMID 20655261 ↗ Jul 2010 “This phase III study assessed the immunogenicity and safety of MenACYW-TT in children compared with a licensed quadrivalent meningococcal vaccine conjugated with diphtheria...” PMID 32852352 ↗ Oct 2020 “A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75...” NCT01547715 ↗ “Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6-7 and 12-13 months, co-administered with...” PMID 41792337 ↗ Mar 2026 “participants 10-25 years of age received 1 booster dose of MenABCWY vaccine at 24 months (M) postprimary series of MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose).” PMID 29329168 ↗ May 2018 “The quadrivalent meningococcal conjugate vaccine MenACWY-CRM has been shown to be immunogenic and well-tolerated in infants and toddlers.” PMID 31279564 ↗ Jul 2019 “Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)” NCT00329849 ↗ “MenACWY-CRM (≥7-≤10 years of age)” NCT01823536 ↗ “MenACWY-CRM (Novartis Vaccines)” PMID 20189491 ↗ Feb 2010 “Biological: MenACWY CRM” NCT00450437 ↗ |
| Known as | MenACWY-CRM197 | “A quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants.” PMID 23566945 ↗ Apr 2013 |
| Known as | MenACWY-D | “This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate...” PMID 20655261 ↗ Jul 2010 |
| Known as | MenACWY-TT | “Different fractional doses of two quadrivalent meningococcal conjugate vaccines (MenACWY-CRM197 (Menveo®) and MenACWY-TT (Nimenrix®)) were administered intradermally to...” PMID 29778515 ↗ May 20188“We evaluated the bactericidal antibody persistence and safety of the quadrivalent meningococcal serogroups A, C, W and Y tetanus-toxoid conjugate vaccine (MenACWY-TT) and the...” PMID 26437712 ↗ Oct 2015 “a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix®) in infants were evaluated.” PMID 39883399 ↗ Jan 2025 |
| Known as | MenACYW-135 conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03537508 ↗ |
| Known as | Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine | “Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)” NCT02986854 ↗ |
| Known as | Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | “Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)” NCT03673462 ↗ |
| Known as | Meningococcal ACWY conjugate vaccine | “A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine...” NCT02986854 ↗5“Biological: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)” NCT00329901 ↗ “Meningococcal ACWY Conjugate Vaccine, MenACWY” NCT02106390 ↗ |
| Known as | meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02097849 ↗ |
| Known as | Nimenrix | “Participants will receive Nimenrix®: 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age” NCT06284915 ↗21“Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization” NCT07133178 ↗ “Participants received 3 doses of Nimenrix® 0.5 mL as an IM injection at dose 1: 2 MoA, dose 2: 4 MoA, and dose 3: 12 to 18 MoA” NCT03547271 ↗ “Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.” NCT02955797 ↗ “received a single dose of Nimenrix® vaccine on Day 0.” NCT03890367 ↗ “Meningitec, NeisVacC, Menitorix, Menveo, Nimenrix” NCT02526394 ↗ “active control meningococcal vaccine (Nimenrix)” PMID 41652122 ↗ Feb 2026 “Nimenrix” NCT04400838 ↗ |
| Known as | Nimenrix(Registered) | “A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED...” NCT03189745 ↗ |
| Known as | Novartis MenACWY-CRM | “Novartis MenACWY-CRM” NCT01274897 ↗ |
| Known as | Novartis Meningococcal ACWY Conjugate Vaccine | “A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents...” NCT01725217 ↗1“Novartis Meningococcal ACWY Conjugate Vaccine” NCT01274897 ↗ |
| Modality | Vaccine | “Meningococcal ACWY Conjugate Vaccine” NCT00262041 ↗ |
| Route | Intramuscular | “administered by IM injection into the anterolateral area of the right thigh” NCT00310856 ↗ |